-
Mashup Score: 0
Rapid development of postexposure therapies is necessary for emerging viral threats such as SARS-CoV-2. Cross et al. demonstrate therapeutic reduction of disease severity using convalescent sera with high concentrations of SARS-CoV-2 neutralizing antibodies in the African green monkey model of COVID-19, suggesting this as a possible treatment approach in humans.
Source: Cell ReportsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4The UTMB Newsroom | UTMB Health | UTMB.edu - 4 year(s) ago
A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston (UTMB) has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus. The study was published today in Nature Communications. “Marburg is a highly virulent disease in the same family as the virus that causes Ebola….
Source: www.utmb.eduCategories: General Medicine News, Latest HeadlinesTweet-
Combination therapy protects macaques against advanced Marburg virus disease Monoclonal antibodies + the antiviral remdesivir @RobertWCross1 @polylepis82 @LarryZeitlin @ZABornholdt @GileadSciences @utmbnews @UTMBProvost @ihii_utmb https://t.co/nykxNhCSLD
-
-
Mashup Score: 2
Rapid development of postexposure therapies is necessary for emerging viral threats such as SARS-CoV-2. Cross et al. demonstrate therapeutic reduction of disease severity using convalescent sera with high concentrations of SARS-CoV-2 neutralizing antibodies in the African green monkey model of COVID-19, suggesting this as a possible treatment approach in humans.
Source: Cell ReportsCategories: Hem/Oncs, Latest HeadlinesTweet-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates [Feb 23, 2021] @RobertWCross1 et al. @CellReports https://t.co/zcxbGkGWYL #openaccess #COVID19 HT @DrMJoyner
-
-
Mashup Score: 0
Rapid development of postexposure therapies is necessary for emerging viral threats such as SARS-CoV-2. Cross et al. demonstrate therapeutic reduction of disease severity using convalescent sera with high concentrations of SARS-CoV-2 neutralizing antibodies in the African green monkey model of COVID-19, suggesting this as a possible treatment approach in humans.
Source: Cell ReportsCategories: Hem/Oncs, Latest HeadlinesTweet-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates [Feb 23, 2021] @RobertWCross1 et al. @CellReports https://t.co/zcxbGkGWYL #openaccess #COVID19 HT @DrMJoyner
-
-
Mashup Score: 0
Rapid development of postexposure therapies is necessary for emerging viral threats such as SARS-CoV-2. Cross et al. demonstrate therapeutic reduction of disease severity using convalescent sera with high concentrations of SARS-CoV-2 neutralizing antibodies in the African green monkey model of COVID-19, suggesting this as a possible treatment approach in humans.
Source: Cell ReportsCategories: Hem/Oncs, Latest HeadlinesTweet-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates [Feb 23, 2021] @RobertWCross1 et al. @CellReports https://t.co/zcxbGkGWYL #openaccess #COVID19 HT @DrMJoyner
-
-
Mashup Score: 3
Rapid development of postexposure therapies is necessary for emerging viral threats such as SARS-CoV-2. Cross et al. demonstrate therapeutic reduction of disease severity using convalescent sera with high concentrations of SARS-CoV-2 neutralizing antibodies in the African green monkey model of COVID-19, suggesting this as a possible treatment approach in humans.
Source: Cell ReportsCategories: Hem/Oncs, Latest HeadlinesTweet-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates [Feb 23, 2021] @RobertWCross1 et al. @CellReports https://t.co/zcxbGkGWYL #openaccess #COVID19 HT @DrMJoyner https://t.co/o3WOrHoEXa
-
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates [Feb 23, 2021] @RobertWCross1 et al. @CellReports https://t.co/zcxbGkGWYL #openaccess #COVID19 HT @DrMJoyner